Home
/
PLUS THERAPEUTICS, INC.
/
Financials
/
Quarterly
PLUS THERAPEUTICS, INC. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that PLUS THERAPEUTICS, INC. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$1.40M
Oct 30, 2025
Q2
2025
Jun 30, 2025
$1.39M
Aug 14, 2025
Q1
2025
Mar 31, 2025
$1.06M
May 30, 2025
Q3
2025
Sep 30, 2024
$1.46M
Oct 30, 2025
Q2
2025
Jun 30, 2024
$1.28M
Aug 14, 2025
Q1
2025
Mar 31, 2024
$1.68M
May 30, 2025
Q2
2018
Jun 30, 2018
$660.0K
Aug 14, 2018
Q1
2018
Mar 31, 2018
$731.0K
May 11, 2018
Q3
2017
Sep 30, 2017
$467.0K
Nov 9, 2017
Q2
2018
Jun 30, 2017
$969.0K
Aug 14, 2018
Q1
2018
Mar 31, 2017
$591.0K
May 11, 2018
Q3
2017
Sep 30, 2016
$731.0K
Nov 9, 2017
Q2
2017
Jun 30, 2016
$1.13M
Aug 11, 2017
Q1
2017
Mar 31, 2016
$1.33M
May 12, 2017
Q3
2016
Sep 30, 2015
$766.0K
Nov 9, 2016
Q2
2016
Jun 30, 2015
$1.61M
Aug 5, 2016
Q1
2016
Mar 31, 2015
$902.0K
May 10, 2016
Q3
2015
Sep 30, 2014
$518.0K
Nov 6, 2015
Q2
2015
Jun 30, 2014
$935.0K
Aug 10, 2015
Q1
2015
Mar 31, 2014
$1.03M
May 11, 2015
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2019
Mar 31, 2019
$703.0K
May 14, 2019
Q3
2018
Sep 30, 2018
$858.0K
Nov 14, 2018
Q1
2019
Mar 31, 2018
$731.0K
May 14, 2019
Q3
2018
Sep 30, 2017
$467.0K
Nov 14, 2018
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($4.42M)
Oct 30, 2025
Q2
2025
Jun 30, 2025
$5.15M
Aug 14, 2025
Q3
2025
Jun 30, 2025
$5.15M
Oct 30, 2025
Q1
2025
Mar 31, 2025
($17.40M)
May 30, 2025
Q2
2025
Mar 31, 2025
($17.40M)
Aug 14, 2025
Q3
2025
Mar 31, 2025
($17.40M)
Oct 30, 2025
Q3
2025
Sep 30, 2024
($2.87M)
Oct 30, 2025
Q2
2025
Jun 30, 2024
($2.94M)
Aug 14, 2025
Q3
2025
Jun 30, 2024
($2.94M)
Oct 30, 2025
Q2
2025
Mar 31, 2024
($3.26M)
Aug 14, 2025
Q3
2025
Mar 31, 2024
($3.26M)
Oct 30, 2025
Q1
2025
Mar 31, 2024
($3.26M)
May 30, 2025
Q3
2024
Sep 30, 2023
($3.22M)
Nov 14, 2024
Q3
2024
Jun 30, 2023
($1.48M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($1.48M)
Aug 14, 2024
Q2
2024
Mar 31, 2023
($4.81M)
Aug 14, 2024
Q1
2024
Mar 31, 2023
($4.81M)
May 15, 2024
Q3
2024
Mar 31, 2023
($4.81M)
Nov 14, 2024
Q3
2023
Sep 30, 2022
($5.22M)
Oct 31, 2023
Q2
2023
Jun 30, 2022
($5.28M)
Aug 14, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($4.48M)
Oct 30, 2025
Q2
2025
Jun 30, 2025
($1.54M)
Aug 14, 2025
Q1
2025
Mar 31, 2025
($3.54M)
May 30, 2025
Q3
2025
Sep 30, 2024
($3.80M)
Oct 30, 2025
Q2
2025
Jun 30, 2024
($3.70M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($3.30M)
May 30, 2025
Q3
2024
Sep 30, 2023
($3.25M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($1.49M)
Aug 14, 2024
Q1
2024
Mar 31, 2023
($4.72M)
May 15, 2024
Q3
2023
Sep 30, 2022
($5.09M)
Oct 31, 2023
Q2
2023
Jun 30, 2022
($5.12M)
Aug 14, 2023
Q1
2023
Mar 31, 2022
($3.93M)
Apr 20, 2023
Q3
2022
Sep 30, 2021
($3.50M)
Oct 20, 2022
Q2
2022
Jun 30, 2021
($2.58M)
Jul 21, 2022
Q1
2022
Mar 31, 2021
($2.48M)
Apr 21, 2022
Q3
2021
Sep 30, 2020
($1.40M)
Oct 21, 2021
Q2
2021
Jun 30, 2020
($2.35M)
Jul 22, 2021
Q1
2021
Mar 31, 2020
($2.44M)
Apr 22, 2021
Q3
2020
Sep 30, 2019
$2.68M
Oct 22, 2020
Q2
2020
Jun 30, 2019
($1.96M)
Aug 10, 2020